Clinical Trial Detail

NCT ID NCT02680795
Title To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Spectrum Pharmaceuticals, Inc
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Belinostat

Age Groups: adult

No variant requirements are available.